Glenn Candace J, Kobraei Katherina B, Russo Jacqueline J
University of Florida College of Medicine, Gainesville, Florida, USA.
Dermatol Online J. 2011 Sep 15;17(9):15.
TNF-α inhibitors, including adalimumab, are increasingly used in the management of inflammatory cutaneous, gastrointestinal, and rheumatologic diseases. An untoward class effect of these medications is the development of new-onset psoriasis, particularly in patients treated for rheumatologic diseases without any personal or family history of cutaneous psoriasis. We report two patients that developed cutaneous and histologic changes consistent with psoriasis while receiving treatment with adalimumab for inflammatory arthridities: one patient with Crohn disease and ankylosing spondylitis who tolerated adalimumab for 15 months before developing psoriasis and another patient with rheumatoid arthritis who developed psoriasis 3 years after starting adalimumab. Both patients experienced rapid resolution of their psoriasis after discontinuation of adalimumab.
包括阿达木单抗在内的肿瘤坏死因子-α抑制剂越来越多地用于治疗炎症性皮肤病、胃肠道疾病和风湿性疾病。这些药物的一个不良类效应是新发银屑病的出现，尤其是在那些没有任何个人或家族皮肤银屑病病史而接受风湿性疾病治疗的患者中。我们报告了两名在接受阿达木单抗治疗炎性关节炎时出现了与银屑病一致的皮肤和组织学改变的患者：一名患有克罗恩病和强直性脊柱炎的患者在耐受阿达木单抗15个月后出现银屑病，另一名类风湿关节炎患者在开始使用阿达木单抗3年后出现银屑病。两名患者在停用阿达木单抗后银屑病均迅速消退。
